

Libraries of Drug Candidates from Peptides and Proteins (Yissum)

code: 6-2006-53

Chaim Gilon, HUJI, Faculty of Science, The Institute of Chemistry

Combinatorial libraries of heterocyclic compounds

Category	Drug Discovery, Small Molecules, Conversion of Peptides and Proteins into drug leads
Development Stage	Ongoing projects in various stages
Patent Status	Patents published in U.S. and Europe, filed in Israel PCT publication number - WO 03/059876
Market Size	The global protein therapeutic market was valued in excess of US\$ 57 billion in 2006, growing at a CAGR of 12.83% till 2010

Highlights

- Preparing libraries of backbone cyclized peptidomietics and macromoecules with conformational diversity, based on active residues from proteins and/or active peptides for screening and selecting drug lead candidates, having improved activity, selectivity, metabolic stability and enhanced intestinal permeability. This technology is applicable to a variety of indications in human medicine, veterinary medicine and in agriculture
- Applying this novel technology to a patented target molecule facilitates the speedy development of drug leads

Our Innovation

• A new technology that converts active regions in proteins and peptides into orally available drug leads.

Key Features

- Faster, more reliable, identification of drug leads
- Enables faster pharmacological studies

Development Milestones

 Cooperation with companies with defined clinical goals and patented molecules to develop drug leads

The Opportunity

- Licensing agreements with cooperation partners to convert their peptides and proteins into drug leads using new technology
- Libraries of drug candidates sold to partners



Contact for more information:

Ariela Markel ☑, VP, Business Development, Healthcare, +972-2-6586608

Yissum Research Development Company of the Hebrew University of Jerusalem Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem P.O. Box 39135, Jerusalem 91390 Israel Telephone: 972-2-658-6688, Fax: 972-2-658-6689